| |
Tuesday, December 19, 2023 | 12pm ET / 9am PT Either you want to implement a CLM, or you don’t know how to fix the processes of the one you have in place. Either is a tough place to be in. Join us in this webinar to learn from a CLM solution implementation expert in the highly regulated field of pharmaceuticals. Register now.
|
|
Today’s Big NewsDec 15, 2023 |
|
Explore new possibilities with Fortrea. Oncology drug development informed by years of insights and powered by our agile approach to clinical trials. Explore Agility.
|
|
| By Nick Paul Taylor Pfizer just swallowed a $43 billion ADC company and still isn’t full. Hours after Pfizer closed the Seagen buyout, Nona Biosciences put out news that the Big Pharma has committed $53 million in upfront and near-term payments for rights to its mesothelin-targeted ADC, dubbed HBM9033. |
|
|
|
By James Waldron With the gold rush in obesity meds showing no sign of abating, Fractyl Health is gearing up to go public as it gathers preclinical evidence that its GLP-1 gene therapy could take on Novo Nordisk’s Wegovy. |
By Nick Paul Taylor Immusoft has administered an engineered B cell to a human for the first time, marking a milestone in its long-running quest to create a new type of medicine. |
Sponsored by SAP America Aparna Seksaria and Kevin Brophy sit down with Fierce Biotech’s Rebecca Williamson to talk about the importance of levelling the playing field by offering leading-edge software solutions to the smaller businesses in the pharma sphere. |
By Max Bayer,Gabrielle Masson Jay Bradner is back after a little more than a year off, taking the R&D reins at Amgen. Genentech swiftly names interim CEO Magargee to the permanent role. Moderna sidelines CCO Garay. |
By Helen Floersh A new form of gene therapy designed to treat the most treatment-resistant form of childhood epilepsy appears to reduce seizures in mice. |
By Helen Floersh A new study led by a Fiercest Women in Life Sciences 2023 awardee points to a cause and a potential treatment for severe nausea and vomiting during pregnancy, with findings in both mice and in humans. |
By Ayla Ellison,Paige Minemyer,Heather Landi,Anastassia Gliadkovskaya,Dave Muoio The Fierce 50 honorees range from tech innovators to researchers developing novel therapies to providers on the frontlines of changing care. This week on "The Top Line," senior editor Paige Minemyer sat down with staff writers Dave Muoio and Anastassia Gliadkovskaya as well as senior editor Heather Landi to discuss a few of the honorees in more detail. |
By Angus Liu Bristol Myers Squibb inked an antibody-drug conjugate (ADC) licensing deal worth up to $8.4 billion. AstraZeneca and Gilead's ADCs passed on China's national insurance scheme. The FDA put three CAR-T candidates from CARsgen Therapeutics on a clinical hold. And more. |
By Ben Adams “Don’t confuse us with BlackRock,” sing the staffers from venture capital firm Blackstone, a major life sciences funding business. It may well be that BlackRock, known for its own controversies, may not want to be associated with Blackstone. |
By Nick Paul Taylor With a new year on the horizon, a clutch of companies have decided on new names for 2024. Pipeline Therapeutics has become Contineum Therapeutics, while Novozymes and Chr. Hansen have picked Novonesis as their new shared identity. |
By Heather Landi More than two dozen healthcare payers and providers are making voluntary safety, security and transparency commitments to the White House regarding the use of artificial intelligence. |
Fierce podcastsDon’t miss an episode |
| | The Fierce 50 honorees range from tech innovators to researchers developing novel therapies to providers on the frontlines of changing care. This week on "The Top Line," senior editor Paige Minemyer sat down with staff writers Dave Muoio and Anastassia Gliadkovskaya as well as senior editor Heather Landi to discuss a few of the honorees in more detail. |
|
|---|
|
|
| WhitepaperThe road to digital health innovation is exciting but complex and requires thoughtful navigation; this whitepaper serves as your guide through this process. S3 Connected Health |
| WhitepaperqPCR Assay Design - Quantify microbial biomarkers with high sensitivity and dynamic range Sponsored by: Diversigen |
| WhitepaperStreamline your clinical cell therapy with our GMP-compliant ribonucleoprotein (RNP) manufacturing as you scale up without compromising on quality to tackle complex regulatory requirements. Sponsored by: Aldevron |
| WhitepaperIf you find yourself grappling with bioanalytical challenges during the drug development process, rest assured that these obstacles can be overcome - discover more! Sponsored by: Sannova Analytical |
| Whitepaper Discover how cloud-based HPC and AI can transform drug discovery and accelerate time-to-market. Download the free solution brief to learn more. Sponsored By: AWS, NVIDIA, and Rescale |
| Executive SummaryBy 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
| WhitepaperLearn about the untapped power of AI-driven insights — where innovation meetings precision, effortlessly unlocking benefits for your organization. Sponsored by: Planisware |
| Whitepaper Medical devices & consumer wearables are starting to overlap, creating risks & opportunities for traditional medical device companies as well as consumer wearables manufacturers. This paper explores pros and cons from both perspectives. Sponsored by: Blue Matter Consulting |
| Whitepaper Improving efficiency and productivity in biologics manufacturing is a longstanding goal within today’s industry, especially now as new and increasingly complex molecules are fundamentally changing technological and operational approaches to drug development. Process intensification can help accelerate this pace of innovation through advanced process development techniques and high productivity manufacturing platforms. Sponsored by: Lonza |
| Whitepaper As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. Sponsored by: Lonza |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| |
|
